SEC Form 4 · accession 0001209191-15-069572
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank H Valone M.D.
Officer — Chief Medical Officer
Period of report
Sep 1, 2015
Accepted (ET)
Sep 3, 2015 · 8:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 1, 2015 | M | 10,000 | $2.35 | A | 94,748 | D | |
| Common StockF1,F2 | Sep 1, 2015 | S | 10,000 | $23.5782 | D | 84,748 | D | |
| Common StockF3 | Sep 1, 2015 | F | 704 | $22.84 | D | 84,044 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $2.35 | Sep 1, 2015 | M | 10,000 | D | — | Dec 3, 2018 | Common Stock | 10,000 | 35,000 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2The shares were sold at prices between $23.15 and $23.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.
- F4Fully vested.